California Poppy

California Poppy Summary

California poppy is a relative of the opium poppy that gives us morphine. This particular member contains a different set of alkaloids with similar, but milder effects.

California Poppy is the official state flower for California but grows throughout the Southern parts of the United States.

Its primary uses — both in modern herbal medicine and traditional herbal medicine — is for treating anxiety, chronic pain, and insomnia. It’s one of the most potent herbal sedatives available.

How Is California Poppy Used?

California poppy is used for its sedative and analgesic effects. It contains a set of alkaloids similar to morphine, though not as strong. It can be used both internally for anxiety, insomnia, and chronic pain, as well as topically for skin irritations and ulcers.

Botanical Information

California poppy is a member of the Papaveraceae family. This family contains roughly 42 genera and about 775 different species. The Eschscholzia genus itself contains about 12 different species.

The species, Eschscholzia californica, is very diverse, as it has been extensively bred commercially and by hobbyists as an ornamental garden flower.

Phytochemistry

The activity of California poppy is carried almost entirely by its isoquinoline alkaloids, which accumulate to roughly 1.6% of the dried aerial parts (the root is richer still) ^{1Reference 1Fedurco M et al. · 2015Modulatory effects of Eschscholzia californica alkaloids on recombinant GABAA receptorsView study →}. The two dominant compounds are the pavine alkaloids californidine and eschscholtzine, with the aporphine N-methyllaurotetanine next most abundant — these are the alkaloids most associated with the herb’s GABA-modulating, sedative and anxiolytic profile ^{1,2Reference 1Fedurco M et al. · 2015Modulatory effects of Eschscholzia californica alkaloids on recombinant GABAA receptorsView study →Reference 2Gafner S et al. · 2006In vitroAlkaloids from Eschscholzia californica and their capacity to inhibit binding of [3H]8-OH-DPAT to 5-HT1A receptors in vitroView study →}.

Present at far lower levels are the protopine-type alkaloids protopine and allocryptopine, and trace amounts of the benzophenanthridines sanguinarine and chelerythrine ^{1Reference 1Fedurco M et al. · 2015Modulatory effects of Eschscholzia californica alkaloids on recombinant GABAA receptorsView study →}. Unlike its relative the opium poppy, Eschscholzia californica contains no morphine or other phenanthrene opiates.

Constituent Summary

Values are the share of total alkaloids in the dried aerial parts; “dominant / minor / trace” reflect relative abundance reported across analyses rather than fixed percentages, and the actual content varies with chemotype, plant part and growing conditions ^{1,2Reference 1Fedurco M et al. · 2015Modulatory effects of Eschscholzia californica alkaloids on recombinant GABAA receptorsView study →Reference 2Gafner S et al. · 2006In vitroAlkaloids from Eschscholzia californica and their capacity to inhibit binding of [3H]8-OH-DPAT to 5-HT1A receptors in vitroView study →}.

Pharmacology & Research

The pharmacological literature on California poppy (Eschscholzia californica) is small and tilted heavily toward preclinical work: a handful of mouse behavioural studies from the 1990s–2000s, several in vitro receptor and enzyme assays, and a genome/biosynthesis literature that dwarfs the therapeutic one. The signal the studies most consistently support is a mild central-nervous-system depressant (sedative/anxiolytic) effect, mapped mechanistically to GABAA and serotonin (5-HT1A) receptor modulation rather than to opioid pathways ^{1,2,4,5Reference 1Fedurco M et al. · 2015Modulatory effects of Eschscholzia californica alkaloids on recombinant GABAA receptorsView study →Reference 2Gafner S et al. · 2006In vitroAlkaloids from Eschscholzia californica and their capacity to inhibit binding of [3H]8-OH-DPAT to 5-HT1A receptors in vitroView study →Reference 4Rolland A et al. · 1991Behavioural effects of the American traditional plant Eschscholzia californica: sedative and anxiolytic propertiesView study →Reference 5Rolland A et al. · 2001Neurophysiological effects of an extract of Eschscholzia californica ChamView study →}. Human data exist but remain weak: the one published positive randomised controlled trial tested California poppy only inside a fixed combination with hawthorn and magnesium, so the herb’s individual contribution is unquantified ^{3Reference 3Hanus M et al. · 2004RCTDouble-blind, randomised, placebo-controlled study of a fixed combination of Crataegus oxyacantha and Eschscholtzia californica and magnesium in mild-to-moderate anxietyView study →}. A completed Phase 3 placebo-controlled monotherapy trial of Eschscholzia tablets for sleep (NCT06795776, n=104) does exist, but its results have not been posted, so it cannot yet be weighed. Almost everything hinges on preparation: alkaloid content varies several-fold between commercial products, and the ethanol tincture that the site lists as the standard dose is pharmacologically distinct from the aqueous tea, which appears far less active at CYP enzymes ^{8,11Reference 8Manda VK et al. · 2016Modulation of CYPs, P-gp, and PXR by Eschscholzia californica and its alkaloidsView study →Reference 11Chauveau A et al. · 2023Alkaloids in commercial preparations of California poppy — quantification, intestinal permeability and microbiota interactionsView study →}.

0. Evidence by indication

Support is an experimental score I’m building — a composite weighted by study type (human > animal > in vitro > review) and study volume. It’s a beta: a fast way to rank strength of evidence at a glance, not a validated metric, and I’ll keep honing the formula over time. Each indication name links down to its write-up.

Indication	Support	Rests on
Anxiolytic	██████░░░░ 60%	Consistent mouse anticonflict data + one combination-product RCT; no published monotherapy human trial.
Sedative / sleep support	█████░░░░░ 54%	Mouse sleep-induction + human qEEG signal; human sleep data only from multi-herb combinations.
Analgesic	████░░░░░░ 42%	Peripheral analgesia in mice, non-opioid; no human analgesia trial.
Antioxidant	████░░░░░░ 38%	In vitro assays on aerial-part extracts; no in vivo data.
Cholinesterase inhibition	███░░░░░░░ 28%	Single 2025 in vitro/in silico screen of extract fractions.
Hypocholesterolemic	███░░░░░░░ 26%	Isolated californidine in a hepatocyte LDLR/PCSK9 assay; constituent-level, not whole herb.

1. Anxiolytic

The anxiolytic claim is the herb’s best-supported use, though the human evidence is indirect. In mice, an aqueous extract produced an anticonflict effect at a low dose (25 mg/kg) — more steps climbed in the staircase test and more time in the lit compartment of a light/dark box — separable from frank sedation, which appeared only at higher doses ^{4Reference 4Rolland A et al. · 1991Behavioural effects of the American traditional plant Eschscholzia californica: sedative and anxiolytic propertiesView study →}. A follow-up study showed the anxiolytic and sedative effects were abolished by flumazenil, implicating the benzodiazepine site of the GABAA receptor ^{5Reference 5Rolland A et al. · 2001Neurophysiological effects of an extract of Eschscholzia californica ChamView study →}. Mechanistically, the aerial-part alkaloid (S)-reticuline acts as a positive allosteric modulator at α3, α5 and α6 GABAA isoforms, while N-methyllaurotetanine contributes 5-HT1A affinity ^{1,2Reference 1Fedurco M et al. · 2015Modulatory effects of Eschscholzia californica alkaloids on recombinant GABAA receptorsView study →Reference 2Gafner S et al. · 2006In vitroAlkaloids from Eschscholzia californica and their capacity to inhibit binding of [3H]8-OH-DPAT to 5-HT1A receptors in vitroView study →}. The only randomised controlled trial (n=264, 3 months) tested a fixed combination of California poppy, hawthorn (Crataegus) and magnesium (Sympathyl) against placebo in mild-to-moderate generalised anxiety, finding a modest but significant advantage on the Hamilton anxiety score (−10.6 vs −8.9; p=0.005) ^{3Reference 3Hanus M et al. · 2004RCTDouble-blind, randomised, placebo-controlled study of a fixed combination of Crataegus oxyacantha and Eschscholtzia californica and magnesium in mild-to-moderate anxietyView study →}.

Gap: No published trial has tested California poppy alone in humans (the completed monotherapy trial NCT06795776 targets sleep, not anxiety, and has no posted results), so its contribution within the anxiety combination product — and the effective monotherapy dose — is unknown.

2. Sedative / sleep support

California poppy’s traditional use as a sleep aid has some experimental backing, again mostly preclinical. In mice the aqueous extract induced sleep and reduced spontaneous locomotion at doses above 100 mg/kg ^{4Reference 4Rolland A et al. · 1991Behavioural effects of the American traditional plant Eschscholzia californica: sedative and anxiolytic propertiesView study →}. In humans, a placebo-controlled quantitative-EEG screen of eight plant extracts detected a measurable acute sedative signal for California poppy alongside increased self-rated tiredness, though the effect was weaker and qualitatively different from the diazepam reference ^{6Reference 6Schulz H et al. · 1998The quantitative EEG as a screening instrument to identify sedative effects of single doses of plant extracts in comparison with diazepamView study →}. The only human sleep-outcome data come from a 4-week open-label pilot (n=40) of a multi-ingredient product combining melatonin, vitamin B6, California poppy, passionflower and lemon balm, which improved sleep-quality scores — a result that cannot be attributed to the poppy specifically ^{9Reference 9Lemoine P et al. · 2019A combination of melatonin, vitamin B6 and medicinal plants in the treatment of mild-to-moderate insomnia: a prospective pilot studyView study →}.

Gap: Every published human sleep result is confounded by co-administered melatonin or other sedative herbs; a single-herb, placebo-controlled Phase 3 sleep trial has completed (NCT06795776, n=104) but its results are not yet posted, and no hypnotic dose is defined.

3. Analgesic

Analgesia is a traditional indication with limited but mechanistically interesting support. In mice, the extract produced peripheral analgesic effects, but — importantly — did not behave like an opioid or a muscle relaxant, and did not protect against pentylenetetrazol convulsions ^{5Reference 5Rolland A et al. · 2001Neurophysiological effects of an extract of Eschscholzia californica ChamView study →}. This distinguishes California poppy from its relative the opium poppy: it contains no morphine or phenanthrene opiates, and its pain effect appears to run through the same GABAergic/benzodiazepine-site mechanism as its sedation rather than through opioid receptors ^{5Reference 5Rolland A et al. · 2001Neurophysiological effects of an extract of Eschscholzia californica ChamView study →}. The protopine-type and pavine alkaloids are the presumed actives.

Gap: No human analgesia trial exists, and the “opioid receptor agonist” description sometimes attached to the herb is not supported by the primary pharmacology, which points to a non-opioid, benzodiazepine-site mechanism.

4. Antioxidant

Antioxidant activity is confined to in vitro work on aerial-part extracts. A 2025 LC-QTOF-MS study characterised four extracts (ethyl acetate, ethanol, 70% ethanol/water, water), identifying 70 compounds including rutin, quercetin glycosides and caffeic-acid derivatives, and measured concentration-dependent radical-scavenging activity across standard assays ^{12Reference 12Kalyniukova A et al. · 2025Comprehensive metabolomic profiling and biological activity analysis of Eschscholzia californica extracts using LC-ESI-QTOF-MSView study →}. The activity tracks the flavonoid fraction rather than the signature alkaloids.

Gap: No animal or human antioxidant data — the effect is measured only in cell-free and cell-culture systems, and the flavonoids responsible are not unique to this herb.

5. Cholinesterase inhibition

A single 2025 study screened E. californica extracts for neuroprotective-enzyme inhibition, reporting anti-acetylcholinesterase activity (highest in the ethanol extract, 2.39 mg GALAE/g) and anti-butyrylcholinesterase activity (highest in ethyl acetate) ^{12Reference 12Kalyniukova A et al. · 2025Comprehensive metabolomic profiling and biological activity analysis of Eschscholzia californica extracts using LC-ESI-QTOF-MSView study →}. Accompanying network-pharmacology and docking work flagged protopine, boldine and (S)-scoulerine as candidate binders of insomnia-related dopaminergic and serotonin-transporter targets ^{12Reference 12Kalyniukova A et al. · 2025Comprehensive metabolomic profiling and biological activity analysis of Eschscholzia californica extracts using LC-ESI-QTOF-MSView study →}.

Gap: This rests on one in vitro/in silico paper with no behavioural or clinical follow-up; the cholinesterase result is a screening observation, not evidence of a cognitive effect.

6. Hypocholesterolemic

This is a constituent-level inference, not a whole-herb finding. In a hepatocyte model, the isolated pavine alkaloid californidine induced LDL-receptor expression comparably to low-dose simvastatin and reduced PCSK9 expression, alongside berberine and other isoquinoline alkaloids ^{13Reference 13Maharjan B et al. · 2022Evaluation of natural isoquinoline alkaloids on LDLR and PCSK9 in hepatocytes as potential hypocholesterolemic agentsView study →}. California poppy is one of several plants that contain such alkaloids, but the whole herb has never been tested for lipid effects.

Gap: The effect is shown only for a purified single molecule in cell culture; there is no evidence the alkaloid reaches relevant concentrations from a normal dose of the herb, and no in vivo or human lipid data.

Mechanisms

Mechanism	Drives	Key compounds
GABAA positive allosteric modulation (benzodiazepine site; flumazenil-reversible)	anxiolytic, sedative, analgesic	(S)-reticuline (N-methyllaurotetanine inactive <30 µM)
5-HT1A / 5-HT7 receptor binding	anxiolytic, sedative	N-methyllaurotetanine
Radical scavenging / anti-lipoperoxidation	antioxidant	rutin, quercetin
Cholinesterase (AChE/BuChE) inhibition	cholinesterase inhibition	protopine, boldine
LDLR induction / PCSK9 suppression	hypocholesterolemic	californidine
CYP3A4/2C9/2C19/2D6 inhibition, PXR activation (ethanol extract; drug-interaction risk)	— (safety)	eschscholtzine, allocryptopine, protopine

Clinical trials

Several trials appear on ClinicalTrials.gov. A single-herb Phase 3 placebo-controlled sleep trial of Eschscholzia tablets has completed (NCT06795776, n=104) but has no posted results; the only published controlled human evidence is a combination-product RCT (California poppy + hawthorn + magnesium) ^{3Reference 3Hanus M et al. · 2004RCTDouble-blind, randomised, placebo-controlled study of a fixed combination of Crataegus oxyacantha and Eschscholtzia californica and magnesium in mild-to-moderate anxietyView study →}; further completed trials tested combination sleep/anxiety supplements (e.g. POWEROFF NCT03364101, Audistim NCT05300594), and one single-herb sleep trial (CALPXT96, NCT02232256) was withdrawn before enrolment.

Completed	Planned	Terminated	Preclinical
4 (1 single-herb, results unposted; 3 combination)	0	1 (withdrawn)	~10

Last checked: July 2026.

Dosage

In the human research, California poppy has only been trialled inside fixed combination products, so no monotherapy dose is defined; the table below reports the doses each study actually used, and their poppy content is mostly undisclosed. These are research doses — not recommendations.

Indication	Preparation	Dose	Est. dried-herb equivalent	Source
Anxiolytic (combination)	Fixed combination tablet (Sympathyl: Eschscholtzia + Crataegus + Mg)	2 tablets twice daily, 3 months (poppy content not disclosed per tablet)	— (proprietary; no marker % given)	3Reference 3Hanus M et al. · 2004RCTDouble-blind, randomised, placebo-controlled study of a fixed combination of Crataegus oxyacantha and Eschscholtzia californica and magnesium in mild-to-moderate anxietyView study →
Sedative / sleep (combination)	Multi-herb capsule (with melatonin, B6, passionflower, lemon balm)	1 capsule/day, 2 weeks	— (proprietary)	9Reference 9Lemoine P et al. · 2019A combination of melatonin, vitamin B6 and medicinal plants in the treatment of mild-to-moderate insomnia: a prospective pilot studyView study →
Anxiolytic / sedative (preclinical)	Aqueous extract, mouse	anticonflict 25 mg/kg; sedation/sleep >100 mg/kg	not translatable to a human dose	4Reference 4Rolland A et al. · 1991Behavioural effects of the American traditional plant Eschscholzia californica: sedative and anxiolytic propertiesView study →

The dried-herb equivalent is left blank because every published human product is a proprietary combination with no disclosed poppy content or marker percentage — inventing a ratio would be unsupported.

Traditional Dosage

Western herbal practice uses the whole aerial parts as a tea or tincture; these traditional doses are not interchangeable with the standardised extracts in the trials above.

System	Preparation	Dose
Western herbal	1:2 liquid extract	20–40 mL/week (~3–6 mL/day)
Western herbal	Dried aerial parts (tea/infusion)	~2 g, up to 2–3× daily
Western herbal	Tincture 1:5	~1–4 mL, up to 3× daily

Safety

California poppy is generally well tolerated at traditional doses, and its constituent alkaloids showed no genotoxicity and no adverse effects in placental-cell safety assays at clinically relevant concentrations ^{10Reference 10Spiess D et al. · 2022In vitroAdvanced in vitro safety assessment of herbal medicines for the treatment of non-psychotic mental disorders in pregnancyView study →}. The most concrete safety signal is pharmacokinetic: the ethanol extract and its alkaloids (eschscholtzine, allocryptopine, protopine) strongly inhibit CYP3A4, CYP2C9, CYP2C19 and CYP2D6 and activate the pregnane X receptor in vitro, so the tincture carries a plausible herb–drug interaction risk with medicines metabolised by these enzymes — notably other sedatives, benzodiazepines and CYP-substrate drugs ^{8Reference 8Manda VK et al. · 2016Modulation of CYPs, P-gp, and PXR by Eschscholzia californica and its alkaloidsView study →}. Notably, the aqueous tea and its main alkaloid californidine did not affect these enzymes, so interaction risk appears preparation-dependent ^{8Reference 8Manda VK et al. · 2016Modulation of CYPs, P-gp, and PXR by Eschscholzia californica and its alkaloidsView study →}. Because the herb acts at the benzodiazepine site of the GABAA receptor, additive sedation with alcohol, benzodiazepines and other CNS depressants is mechanistically expected ^{1,5Reference 1Fedurco M et al. · 2015Modulatory effects of Eschscholzia californica alkaloids on recombinant GABAA receptorsView study →Reference 5Rolland A et al. · 2001Neurophysiological effects of an extract of Eschscholzia californica ChamView study →}.

Scope: one in vitro study characterised the CYP450/P-gp/PXR interactions ^{8Reference 8Manda VK et al. · 2016Modulation of CYPs, P-gp, and PXR by Eschscholzia californica and its alkaloidsView study →}; there are no clinical drug-interaction studies. Pregnancy safety rests on a single in vitro placental-cell study ^{10Reference 10Spiess D et al. · 2022In vitroAdvanced in vitro safety assessment of herbal medicines for the treatment of non-psychotic mental disorders in pregnancyView study →} — there are no human data. Absence of reports is not evidence of safety.

Pregnancy & lactation

Not established — avoid without professional advice. No clinical safety data exist for California poppy in pregnancy or lactation. In vitro placental-cell (BeWo b30) work found extracts and the alkaloid protopine were non-cytotoxic and non-genotoxic at usual clinical doses, which is reassuring but not equivalent to human safety evidence ^{10Reference 10Spiess D et al. · 2022In vitroAdvanced in vitro safety assessment of herbal medicines for the treatment of non-psychotic mental disorders in pregnancyView study →}. Given the documented CYP-inhibiting alkaloids and the absence of human data, avoidance during pregnancy and breastfeeding is the prudent default.

References

1. Fedurco M, Gregorová J, Šebrlová K, et al. Modulatory effects of Eschscholzia californica alkaloids on recombinant GABAA receptors. Biochemistry Research International. 2015;2015:617620. https://pubmed.ncbi.nlm.nih.gov/26509084/
2. Gafner S, Dietz BM, McPhail KL, et al. Alkaloids from Eschscholzia californica and their capacity to inhibit binding of [3H]8-OH-DPAT to 5-HT1A receptors in vitro. Journal of Natural Products. 2006;69(3):432–435. https://pubmed.ncbi.nlm.nih.gov/16562853/
3. Hanus M, Lafon J, Mathieu M. Double-blind, randomised, placebo-controlled study of a fixed combination of Crataegus oxyacantha and Eschscholtzia californica and magnesium in mild-to-moderate anxiety. Current Medical Research and Opinion. 2004;20(1):63–71. https://pubmed.ncbi.nlm.nih.gov/14741074/
4. Rolland A, Fleurentin J, Lanhers MC, et al. Behavioural effects of the American traditional plant Eschscholzia californica: sedative and anxiolytic properties. Planta Medica. 1991;57(3):212–216. https://pubmed.ncbi.nlm.nih.gov/1680240/
5. Rolland A, Fleurentin J, Lanhers MC, et al. Neurophysiological effects of an extract of Eschscholzia californica Cham. (Papaveraceae). Phytotherapy Research. 2001;15(5):377–381. https://pubmed.ncbi.nlm.nih.gov/11507727/
6. Schulz H, Jobert M, Hübner WD. The quantitative EEG as a screening instrument to identify sedative effects of single doses of plant extracts in comparison with diazepam. Phytomedicine. 1998;5(6):449–458. https://pubmed.ncbi.nlm.nih.gov/23196028/
7. Sarris J, McIntyre E, Camfield DA. Plant-based medicines for anxiety disorders, part 1: a review of preclinical studies. CNS Drugs. 2013;27:207–219. https://pubmed.ncbi.nlm.nih.gov/23436255/
8. Manda VK, Ibrahim MA, Dale OR, et al. Modulation of CYPs, P-gp, and PXR by Eschscholzia californica and its alkaloids. Planta Medica. 2016;82(6):551–558. https://pubmed.ncbi.nlm.nih.gov/27054913/
9. Lemoine P, Bablon JC, Da Silva C. A combination of melatonin, vitamin B6 and medicinal plants in the treatment of mild-to-moderate insomnia: a prospective pilot study. Complementary Therapies in Medicine. 2019;45:104–108. https://pubmed.ncbi.nlm.nih.gov/31331545/
10. Spiess D, Winker M, Dolder Behna A, et al. Advanced in vitro safety assessment of herbal medicines for the treatment of non-psychotic mental disorders in pregnancy. Frontiers in Pharmacology. 2022;13:882997. https://pubmed.ncbi.nlm.nih.gov/35814220/
11. Chauveau A, Boisard S, Marchand P, et al. Alkaloids in commercial preparations of California poppy — quantification, intestinal permeability and microbiota interactions. Biomedicine & Pharmacotherapy. 2023. https://pubmed.ncbi.nlm.nih.gov/37673017/
12. Kalyniukova A, et al. Comprehensive metabolomic profiling and biological activity analysis of Eschscholzia californica extracts using LC-ESI-QTOF-MS. Food Science & Nutrition. 2025. https://doi.org/10.1002/fsn3.70885 · https://pubmed.ncbi.nlm.nih.gov/40909255/
13. Maharjan B, et al. Evaluation of natural isoquinoline alkaloids on LDLR and PCSK9 in hepatocytes as potential hypocholesterolemic agents. Bioorganic Chemistry. 2022;121:105686. https://pubmed.ncbi.nlm.nih.gov/35217376/